Program
Human Growth Hormone
Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 340 open or running | phase 4since Sep 13, 2005 | Feb 1, 2005 | none ahead |
| Changchun GeneScience Pharmaceutical | 194 open or running | phase 4since Nov 27, 2014 | Apr 21, 2011 | Apr 28, 2027phase 4 · NCT07691125 |
| Merck KGaA, Darmstadt, Germany | 190 open or running | phase 4since Nov 18, 2005 | May 13, 2004 | none ahead |
| Pfizer | 180 open or running | phase 4since Feb 5, 2007 | Sep 9, 2005 | none ahead |
| Eli Lilly | 100 open or running | phase 4since Dec 15, 2005 | Sep 12, 2005 | none ahead |
| LG Chem | 40 open or running | phase 4since Nov 10, 2016 | Dec 29, 2005 | none ahead |
| Daewoong Pharmaceutical | 20 open or running | phase 3since Jan 19, 2016 | Sep 23, 2011 | none ahead |
| Ferring Pharmaceuticals | 20 open or running | phase 3since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 4since Dec 4, 2014 | Mar 11, 2004 | none ahead |
| Ipsen | 20 open or running | phase 4since Aug 24, 2011 | Oct 5, 2005 | none ahead |
| altus-pharmaceuticals | 10 open or running | phase 2since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Nov 28, 2011 | Nov 28, 2011 | none ahead |
| Clinique Ovo | 10 open or running | phase 4since Oct 24, 2012 | Oct 24, 2012 | none ahead |
| Sanofi | 10 open or running | phase 3since Mar 23, 2007 | Mar 23, 2007 | none ahead |
| zhongshan-sansure-hygene-biomedicine-co-ltd | 11 open or running | phase 3since Sep 2, 2026 | Sep 2, 2026 | Oct 2028phase 3 · NCT07815626 |
Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Dec 16, 2009.
- Mar 28, 2017Phase 2 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT03104010 · 180 enrolled · China
- Jul 14, 20172 phase 2 studies in DwarfismChangchun GeneScience Pharmaceutical · NCT03255694, NCT03221088
- Jul 18, 2017Phase 3 study in Small for Gestational Age InfantChangchun GeneScience Pharmaceutical · NCT03245333 · 120 enrolled · China
- Jul 24, 2017Phase 4 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT03249480 · 900 enrolled · China
- Sep 19, 2017Phase 4 study in Growth RetardationChangchun GeneScience Pharmaceutical · NCT03290235 · 1,500 enrolled · China
- Apr 28, 2018Phase 3 study in DwarfismChangchun GeneScience Pharmaceutical · NCT03535415 · 68 enrolled · China
- May 30, 2018Phase 3 study in Prader-Willi SyndromeChangchun GeneScience Pharmaceutical · NCT03554031 · 30 enrolled · China
- Dec 21, 2018Phase 3 study in Dwarfism, PituitaryPfizer · NCT03831880 · 87 enrolled · United States, Bulgaria, Czechia and more
- Sep 9, 2019Phase 1 study in Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersLG Chem · NCT04085224 · 24 enrolled · Korea, Republic of
- Apr 25, 2022Phase 4 study in AchondroplasiaChangchun GeneScience Pharmaceutical · NCT05353192 · 39 enrolled · China
- Aug 9, 2023Phase 3 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT06024967 · 180 planned
- Apr 14, 2026Phase 1 study in HealthyPfizer · NCT07542886 · 27 enrolled · Belgium
- Jul 1, 2026Phase 4 study in Short Bowel SyndromeChangchun GeneScience Pharmaceutical · NCT07691125 · 100 planned · China
- Sep 2, 2026zhongshan-sansure-hygene-biomedicine-co-ltd’s first study: phase 3 study in Idiopathic Short Stature (ISS)New to zhongshan-sansure-hygene-biomedicine-co-ltdzhongshan-sansure-hygene-biomedicine-co-ltd · NCT07815626 · 240 planned · China
Ahead
- Apr 28, 2027Primary completion: phase 4 study in Short Bowel SyndromeChangchun GeneScience Pharmaceutical · NCT07691125
- Oct 2028Primary completion: phase 3 study in Idiopathic Short Stature (ISS)zhongshan-sansure-hygene-biomedicine-co-ltd · NCT07815626
- Jun 2030Primary completion: phase 2 study in DwarfismChangchun GeneScience Pharmaceutical · NCT03255694
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lonapegsomatropinrule | ascendis-pharma-endocrinology-division-a-s | phase 3 | 6 |
Studies
The newest 60 of 117 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07815626Idiopathic Short Stature (ISS) · China | 3 | Not yet recruiting | zhongshan-sansure-hygene-biomedicine-co-ltd | Oct 2028 | 240 |
| NCT07691125Short Bowel Syndrome · China | 4 | Recruiting | Changchun GeneScience Pharmaceutical | Apr 28, 2027 | 100 |
| NCT07542886Healthy · Belgium | 1 | Completed | Pfizer | Jun 25, 2026 | 27 |
| NCT06024967Dwarfism, Pituitary | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | May 1, 2025 | 180 |
| NCT05353192Achondroplasia · China | 4 | Completed | Changchun GeneScience Pharmaceutical | Aug 25, 2025 | 39 |
| NCT04085224Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Jan 2, 2020 | 24 |
| NCT03831880Dwarfism, Pituitary · United States, Bulgaria, Czechia and more | 3 | Completed | Pfizer | Aug 28, 2020 | 87 |
| NCT03554031Prader-Willi Syndrome · China | 3 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jan 2020 | 30 |
| NCT03535415Dwarfism · China | 3 | UNKNOWN | Changchun GeneScience Pharmaceutical | Sep 2020 | 68 |
| NCT03290235Growth Retardation · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Oct 2020 | 1,500 |
| NCT03249480Dwarfism, Pituitary · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Aug 2017 | 900 |
| NCT03245333Small for Gestational Age Infant · China | 3 | UNKNOWN | Changchun GeneScience Pharmaceutical | Dec 2017 | 120 |
| NCT03255694Dwarfism · China | 2 | Active, not recruiting | Changchun GeneScience Pharmaceutical | Jun 2030 | 360 |
| NCT03221088Dwarfism · China | 2 | UNKNOWN | Changchun GeneScience Pharmaceutical | Dec 2018 | 360 |
| NCT03104010Dwarfism, Pituitary · China | 2 | UNKNOWN | Changchun GeneScience Pharmaceutical | Feb 2022 | 180 |
| NCT02976675Dwarfism, Pituitary · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jun 2017 | 600 |
| NCT03015909Dwarfism · Korea, Republic of | 4 | Completed | LG Chem | Dec 21, 2017 | 116 |
| NCT02908958Dwarfism, Pituitary · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jun 2017 | 900 |
| NCT02693522Dwarfism, Pituitary · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Dec 2004 | 52 |
| NCT02380235Dwarfism, Pituitary · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jun 2017 | 600 |
| NCT02375620Short Stature Children Born Small for Gestational Age (SGA) · China | 2 | Active, not recruiting | Changchun GeneScience Pharmaceutical | Dec 12, 2023 | 96 |
| NCT02311894Dwarfism, Pituitary · United States | 4 | Completed | Hoffmann-La Roche | Nov 8, 2017 | 82 |
| NCT02314676Dwarfism, Pituitary · China | 4 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jul 2017 | 900 |
| NCT01927861Genetic Diseases, Inborn · Japan | 3 | Completed | Novo Nordisk | Jul 12, 2018 | 51 |
| NCT01859949Dwarfism · Japan | 4 | Completed | Pfizer | Aug 2015 | 62 |
| NCT01806298Dwarfism, Pituitary · Australia, Germany, Sweden and more | 4 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2016 | 78 |
| NCT01778023Growth Disorders · Korea, Republic of | 3 | Completed | Novo Nordisk | Dec 17, 2014 | 54 |
| NCT01746862Idiopathic Short Stature · Korea, Republic of | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2014 | 90 |
| NCT01734486Genetic Diseases, Inborn · France | 4 | Completed | Novo Nordisk | May 21, 2003 | 31 |
| NCT01734447Foetal Growth Problem · France | 4 | Completed | Novo Nordisk | Apr 30, 2003 | 57 |
| NCT01715324Infertility · Canada | 4 | Completed | Clinique Ovo | Jul 2021 | 288 |
| NCT01698944Dwarfism, Pituitary · Greece | 4 | Terminated | Novo Nordisk | Nov 18, 2002 | 7 |
| NCT01697644Foetal Growth Problem · Netherlands | 4 | Completed | Novo Nordisk | May 2005 | 75 |
| NCT01613573Dwarfism, Pituitary | 1 | Completed | Changchun GeneScience Pharmaceutical | Oct 2010 | 12 |
| NCT01563926Genetic Diseases, Inborn · Israel | 3 | Completed | Novo Nordisk | Oct 10, 2002 | 168 |
| NCT01562834Dwarfism, Pituitary · France | 4 | Completed | Novo Nordisk | Dec 1, 2002 | 22 |
| NCT01518062Genetic Diseases, Inborn · Netherlands | 4 | Completed | Novo Nordisk | Sep 2003 | 65 |
| NCT01518036Genetic Diseases, Inborn · United Kingdom | 3 | Completed | Novo Nordisk | Apr 11, 2004 | 57 |
| NCT01512095Growth Disorders | 1 | Withdrawn | Novo Nordisk | Nov 2013 | 0 |
| NCT01529944Genetic Diseases, Inborn · Sweden | 3 | Completed | Novo Nordisk | Oct 2008 | 22 |
| NCT01529840Genetic Diseases, Inborn · Sweden | 3 | Completed | Novo Nordisk | Sep 2005 | 24 |
| NCT01502137Renal Insufficiency, Chronic · Germany | 1 | Completed | Novo Nordisk | Nov 2005 | 21 |
| NCT01502124Growth Hormone Disorder · United States | 3 | Completed | Novo Nordisk | Mar 5, 2003 | 78 |
| NCT01495468Dwarfism, Pituitary · China | 3 | Completed | Changchun GeneScience Pharmaceutical | Jan 2008 | 343 |
| NCT01494779Dwarfism, Pituitary · Brazil | 1 | UNKNOWN | Azidus Brasil | Jun 2013 | 32 |
| NCT01440686Dwarfism, Pituitary · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Dec 2011 | 40 |
| NCT01438801Idiopathic Short Stature | 4 | Withdrawn | Ipsen | May 31, 2013 | 0 |
| NCT01400698Children Born With Serious Intra-uterine Growth Retardation | 3 | Completed | Merck KGaA, Darmstadt, Germany | Feb 2010 | 91 |
| NCT01401244Genetic Diseases, Inborn · United States | 1 | Completed | Novo Nordisk | Sep 27, 2011 | 30 |
| NCT01342146Dwarfism, Pituitary | 2 | Completed | Changchun GeneScience Pharmaceutical | Jan 2007 | 101 |
| NCT01237340Dwarfism, Pituitary · United States | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Dec 2011 | 59 |
| NCT01187550Dwarfism, Pituitary | 4 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2008 | 214 |
| NCT01157793Dwarfism | 4 | Completed | Merck KGaA, Darmstadt, Germany | Feb 2005 | 34 |
| NCT01111019Hypochondroplasia · France | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jan 17, 2017 | 19 |
| NCT01077960Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome · United States, Canada | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2006 | 126 |
| NCT01073605Growth Disorders · France | 3 | Completed | Pfizer | May 2009 | 208 |
| NCT01067352Infant, Small for Gestational Age · Italy | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Jul 2009 | 25 |
| NCT01066052Turner Syndrome · France | 4 | Completed | Merck KGaA, Darmstadt, Germany | Mar 31, 1999 | 115 |
| NCT01034735Failure to Thrive · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2008 | 30 |
| NCT01034202Growth Hormone Disorder · Denmark | 1 | Completed | Novo Nordisk | Jan 2008 | 56 |
How it is read
Names in the registry
- “somatropin”, 52 entries
- “Somatropin”, 27 entries
- “PEG-somatropin”, 13 entries
- “Saizen®”, 6 entries
- “Genotropin”, 5 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 38 studies
- Turner Syndrome, 10 studies
- Dwarfism, 6 studies
- Growth Disorders, 4 studies
- Genetic Diseases, Inborn, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.